Note 13. WARRANTS |
We
have the following shares of common stock reserved for exercise of the warrants outstanding as of March 31, 2015:
|
|
March
31, 2015 |
|
|
|
|
|
|
Weighted |
|
|
|
|
|
|
Average |
|
|
|
|
|
|
Exercise |
|
|
|
Shares |
|
|
Price |
|
Warrants outstanding
beginning of year |
|
|
20,709,845 |
|
|
$ |
0.23 |
|
Warrants exercised |
|
|
- |
|
|
|
0.00 |
|
Warrants granted |
|
|
1,118,068 |
|
|
|
0.16 |
|
Warrants expired |
|
|
(3,886,800 |
) |
|
|
(0.33 |
) |
|
|
|
|
|
|
|
|
|
Warrants outstanding
end of period |
|
|
17,941,113 |
|
|
$ |
0.20 |
|
The
weighted exercise price and weighted fair value of the warrants granted by us as of March 31, 2015, are as follows:
|
|
March
31, 2015 |
|
|
|
Weighted |
|
|
|
|
|
|
Average |
|
|
Weighted |
|
|
|
Exercise |
|
|
Average |
|
|
|
Price |
|
|
Fair
Value |
|
Weighted
average of warrants granted during the three months whose exercise price exceeded fair market value at the date of grant |
|
$ |
0.16 |
|
|
$ |
0.16 |
|
|
|
|
|
|
|
|
|
|
The
following table summarizes information about fixed-price warrants outstanding:
|
|
|
Number |
|
Average |
|
|
|
Range
of |
|
|
Outstanding
at |
|
Remaining |
|
Weighted |
|
Exercise |
|
|
March 31, |
|
Contractual |
|
Average |
|
Prices |
|
|
2015 |
|
Life |
|
Exercise
Price |
|
$ |
0.33 |
|
|
|
1,284,000 |
|
1
Months |
|
$ |
0.33 |
|
$ |
0.33 |
|
|
|
120,000 |
|
2 Months |
|
$ |
0.33 |
|
$ |
0.33 |
|
|
|
249,600 |
|
3 Months |
|
$ |
0.33 |
|
$ |
0.46 |
|
|
|
600,000 |
|
5 Months |
|
$ |
0.46 |
|
$ |
0.46 |
|
|
|
150,000 |
|
10 Months |
|
$ |
0.46 |
|
$ |
0.85 |
|
|
|
40,000 |
|
13 Months |
|
$ |
0.85 |
|
$ |
0.40 |
|
|
|
333,333 |
|
17 Months |
|
$ |
0.40 |
|
$ |
0.33 |
|
|
|
439,637 |
|
22 Months |
|
$ |
0.33 |
|
$ |
0.16 |
|
|
|
750,000 |
|
24 Months |
|
$ |
0.16 |
|
$ |
0.30 |
|
|
|
964,912 |
|
40 Months |
|
$ |
0.30 |
|
$ |
0.30 |
|
|
|
4,824,561 |
|
41 Months |
|
$ |
0.30 |
|
$ |
0.06 |
|
|
|
7,067,002 |
|
43 Months |
|
$ |
0.06 |
|
$ |
0.16 |
|
|
|
1,118,068 |
|
47 Months |
|
$ |
0.16 |
|
|
|
|
|
|
17,941,113 |
|
|
|
|
|
|
|